• Consensus Rating: Buy
  • Consensus Price Target: $37.33
  • Forecasted Upside: 145.29%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$15.22
▼ -0.73 (-4.58%)

This chart shows the closing price for CRIS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Curis Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CRIS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CRIS

Analyst Price Target is $37.33
▲ +145.29% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Curis in the last 3 months. The average price target is $37.33, with a high forecast of $60.00 and a low forecast of $26.00. The average price target represents a 145.29% upside from the last price of $15.22.

This chart shows the closing price for CRIS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 3 investment analysts is to buy stock in Curis. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/27/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/25/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/25/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/24/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/22/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/20/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/20/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/19/2024

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/9/2024HC WainwrightLower TargetBuy ➝ Buy$51.00 ➝ $26.00Low
11/17/2023Truist FinancialInitiated CoverageBuy$26.00Low
9/25/2023HC WainwrightReiterated RatingBuy ➝ BuyLow
9/7/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$60.00Low
8/4/2023HC WainwrightReiterated RatingBuy ➝ Buy$120.00Low
7/7/2023HC WainwrightLower Target$180.00 ➝ $120.00Low
11/10/2022HC WainwrightLower TargetBuy$320.00 ➝ $180.00Low
9/21/2022Cantor FitzgeraldReiterated RatingOverweightLow
4/5/2022Cantor FitzgeraldLower Target$240.00 ➝ $80.00High
4/5/2022B. RileyLower TargetBuy$440.00 ➝ $200.00High
4/4/2022Raymond JamesDowngradeOutperform ➝ Market Perform$300.00High
4/1/2022Cantor FitzgeraldReiterated RatingOverweightN/A
3/2/2022Cantor FitzgeraldLower Target$480.00 ➝ $240.00High
10/13/2021Raymond JamesInitiated CoverageOutperform$300.00High
8/4/2021B. RileyReiterated RatingBuy$440.00Medium
6/14/2021HC WainwrightReiterated RatingBuy$400.00High
6/14/2021B. RileyReiterated RatingBuy$440.00Medium
5/13/2021B. RileyBoost TargetPositive ➝ Buy$380.00 ➝ $440.00High
5/13/2021Cantor FitzgeraldBoost TargetOverweight$300.00 ➝ $480.00High
3/24/2021B. RileyInitiated CoverageBuy$380.00High
3/17/2021JonestradingBoost TargetBuy$280.00 ➝ $360.00High
1/15/2021HC WainwrightBoost TargetBuy$180.00 ➝ $320.00N/A
12/16/2020Cantor FitzgeraldBoost TargetPositive ➝ Overweight$80.00 ➝ $300.00Low
12/8/2020HC WainwrightBoost TargetBuy$100.00 ➝ $180.00N/A
11/24/2020HC WainwrightInitiated CoverageBuy$100.00Medium
7/29/2020LaidlawInitiated CoverageBuy$100.00Medium
7/16/2020Cantor FitzgeraldInitiated CoverageOverweight$80.00 ➝ $80.00High
(Data available from 4/19/2019 forward)

News Sentiment Rating

0.52 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
9/22/2023
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/22/2023
  • 2 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/21/2023
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/21/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/20/2024
  • 3 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
2/19/2024
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/20/2024
  • 3 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/19/2024

Current Sentiment

  • 3 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
Curis logo
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreement with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed four programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.
Read More

Today's Range

Now: $15.22
Low: $14.63
High: $16.50

50 Day Range

MA: $11.51
Low: $9.51
High: $16.80

52 Week Range

Now: $15.22
Low: $3.80
High: $19.60

Volume

19,560 shs

Average Volume

36,769 shs

Market Capitalization

$89.71 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.72

Frequently Asked Questions

What sell-side analysts currently cover shares of Curis?

The following Wall Street analysts have issued reports on Curis in the last twelve months: Cantor Fitzgerald, HC Wainwright, StockNews.com, and Truist Financial Co..
View the latest analyst ratings for CRIS.

What is the current price target for Curis?

3 Wall Street analysts have set twelve-month price targets for Curis in the last year. Their average twelve-month price target is $37.33, suggesting a possible upside of 145.3%. Cantor Fitzgerald has the highest price target set, predicting CRIS will reach $60.00 in the next twelve months. Truist Financial Co. has the lowest price target set, forecasting a price of $26.00 for Curis in the next year.
View the latest price targets for CRIS.

What is the current consensus analyst rating for Curis?

Curis currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CRIS will outperform the market and that investors should add to their positions of Curis.
View the latest ratings for CRIS.

What other companies compete with Curis?

How do I contact Curis' investor relations team?

Curis' physical mailing address is 128 Spring Street Building C - Suite 500, LEXINGTON MA, 02421. The biotechnology company's listed phone number is (617) 503-6500 and its investor relations email address is [email protected]. The official website for Curis is www.curis.com. Learn More about contacing Curis investor relations.